

Under the aegis of



# Pink Conclave

**SABCS Highlights 2024**  
**Potential Practice Changing Breast Cancer Trials**

**SAVE THE DATES**

**Virtual**  
Conference



**9th & 10th January, 2025**



**06:00 PM - 09:30 PM IST**



**Program Convenor**

**Dr. Naresh Somani**

Director Oncology & HOD,  
Medical Oncology, HCG Cancer Center  
& Somani Hospital, Jaipur

**REGISTER**

**NOW**

Registration is Free But Mandatory

<https://streamgo.in/SABCS2024/>



# Pink Conclave

## SABCS Highlights 2024 Potential Practice Changing Breast Cancer Trials

 9th & 10th January, 2025

 06:00 PM - 09:30 PM IST

TIME	TOPIC
6:25 PM - 6:30 PM	Welcome, Introduction & Opening Remarks
6:30 PM - 6:37 PM	Evaluating Image-Guided Optimization of Neoadjuvant Chemotherapy Duration in Stage II and III HER2-Positive Breast Cancer
6:37 PM - 6:44 PM	No Axillary Surgery Versus Axillary Sentinel Lymph Node Biopsy in Patients with Early invasive Breast Cancer and Breast-Conserving Surgery: Final Primary Results of the Intergroup-Sentinel-Mamma (INSEMA) Trial
<b>EBC 1</b>	
6:44 PM - 6:51 PM	Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ The COMET Randomized Clinical Trial
6:51 PM - 6:58 PM	-Exclusive endocrine therapy or radiation therapy in women aged 70+ years with luminal-like early breast cancer (EUROPA): preplanned interim analysis of a randomized phase 3 trial.

TIME	TOPIC
6:58 PM - 7:05 PM	Most Patients With Intermediate-risk Breast Cancer May Safely Avoid Chest Wall Irradiation After Mastectomy to demonstrate that omitting sentinel lymph node biopsies (SLNB) is safe for clinically node-negative patients :NSEMA
7:05 PM - 7:12 PM	Patients with intermediate-risk breast cancer had similar rates of 10-year overall survival whether or not they underwent chest wall irradiation (CWI) after mastectomy, according to results from the BIG 2-04 MRC SUPREMO clinical trial
6:44 PM - 6:51 PM	Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ The COMET Randomized Clinical Trial
7:12 PM - 7:52 PM	<b>Panel Discussion</b>
7:52 PM - 8:12 PM	<b>Sponsored Talk</b>
<b>EBC 2</b>	
8:12 PM - 8:19 PM	The OlympiA trial is a phase III clinical trial that demonstrated that adjuvant olaparib (Lynparza) significantly improved overall survival (OS), invasive disease-free survival (IDFS), and distant disease-free survival (DDFS) in patients with high-risk, early breast cancer
8:19 PM-8:26PM	SABCS 2024: Longer-term NATALEE data shows durable reduction in distant recurrence in broad population of patients with early breast cancer
8:26 PM - 8:33 PM	Impact of Tamoxifen Only after Breast Conservation Surgery for “Good Risk” Duct Carcinoma in Situ: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial
8:33 PM - 8:40 PM	Nab-Paclitaxel vs. Solvent-Based Paclitaxel in High-Risk eBC - Final Survival Results of WSG ADAPT HR+/HER2- Trial
8:40PM-9:10 PM	<b>Sponsored Talk</b>
9:10pm-9:15 PM	<b>Closing Remarks</b>



# Pink Conclave

## SABCS Highlights 2024 Potential Practice Changing Breast Cancer Trials

 9th & 10th January, 2025

 06:00 PM - 09:30 PM IST

**DAY - 2**

### TIME

### TOPIC

6:30 PM - 6:35 PM

Welcome, Introduction & Opening Remarks

#### Metastatic Breast Cancer

6:35 PM - 6:42 PM

PATINA: a Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor- Positive (HR+)/ HER-Positive Metastatic Breast Cancer

6:42 PM - 6:49 PM

HER2 Loss following treatment with TDX in patients with MBC

6:49PM - 6:56 PM

The DESTINY-Breast06 phase 3 trial showed that trastuzumab deruxtecan significantly improved progression-free survival in HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

6:56PM - 7:02 PM

The PADMA phase 3 trial demonstrated that combining palbociclib with endocrine therapy significantly outperformed standard chemotherapy in treating high-risk hormone receptor-positive/ HER2-negative metastatic breast cancer.

# TIME

# TOPIC

7:02PM - 7:09 PM

EMBER-3 Trial: Imlunestrant Plus Abemaciclib Improves Survival in Advanced Breast Cancer

7:09 PM - 7:16 PM

P Verify :No significant overall survival (OS) benefit was observed when comparing 3 CDK4/6 inhibitor combinations in hormone receptor-positive/HER2-negative metastatic breast cancer. Evaluated CDK4/6 inhibitor combinations included palbociclib (Ibrance) plus an aromatase inhibitor (AI), ribociclib (Kisqali) plus AI, and abemaciclib (Verzenio) plus AI

7:16 PM - 7:55 PM

**Panel Discussion**

**Industry sponsored session**

7:55 PM - 8:25 PM

**Case Based Panel Discussion- HR+/HER2-low MBC**

8:25 PM -8:40 PM

**Pearls of Wisdom**

8:40 PM -9:00 PM

**QUIZ for All**

